The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging commercial partnerships via PCI to smooth the way from ideas to FDA-approved therapies.
The article maps the journey of how PCI came to be, describes how PCI handles 750+ commercial agreements per year, and details PCI’s role in empowering Penn researchers to accelerate the advancement of their discoveries by positioning them as active research and development partners with relevant companies. Read more here.